Abstract Search

ea0037gp.22.04 | Pituitary–Therapy of Cushing's disease | ECE2015

Long-term (5 years) treatment of Cushing's disease with pasireotide

Petersenn Stephan , Salgado Luiz R , Schopohl Jochen , Portocarrero-Ortiz Lesly , Arnaldi Giorgio , Lacroix Andre , Ravichandran Shoba , Kandra Albert , Bagulho Teresa , Biller Beverly MK

Background: In a large 12-month Phase III study, pasireotide led to rapid and sustained decreases in UFC and provided clinical benefit in patients with Cushings disease. Here, we report data following an open-label, open-ended extension.Methods: 162 patients with persistent/recurrent or de novo Cushings disease were randomized in the core study. 58 patients with mean UFC≤ULN or clinical benefit at month 12 entered the extension...

0 shares

ePoster

ea0037ep811 | Pituitary: clinical | ECE2015

Ongoing, open-label, multicenter, expanded-access study demonstrating the safety and efficacy of pasireotide sc in patients with Cushing's disease

Salgado Luiz R , Stalla Gunter K , Mazzuco Tania Longo , Geer Eliza B , Pedroncelli Alberto M , Ye Moncy , Kandra Albert , Limumpornpetch Padiporn

Background: Pasireotide (Signifor®), a multireceptor-targeted somatostatin analogue, was initially approved in Europe and the USA in 2012 for treating adult patients with Cushings disease for whom surgery is not an option/has failed. This expanded-access study allowed patients to receive pasireotide until regulatory approval was obtained in their country, and collected further safety/efficacy data. Here we report an interim analysis of this on...

0 shares

ePoster

Endocrine Abstracts

Long-term (5 years) treatment of Cushing's disease with pasireotide

Ongoing, open-label, multicenter, expanded-access study demonstrating the safety and efficacy of pasireotide sc in patients with Cushing's disease

BiosciAbstracts